Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial

Wallace Daniel J.; Strand Vibeke; Merrill Joan T.; Popa Serghei; Spindler Alberto J.; Eimon Alicia; Petri Michelle; Smolen Josef S.; Wajdula Joseph; Christensen Jared; Li Cheryl; Diehl Annette; Vincent Michael S.; Beebe Jean; Healey Paul; Sridharan Sudhakar

首页> 外文期刊>Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research >Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial

【24h】

Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial

机译：白细胞介素6单克隆抗体治疗系统性红斑狼疮的疗效和安全性：A II期剂量 - 范围随机对照试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objectives This phase II trial evaluated the efficacy and safety of an interleukin (IL) 6 monoclonal antibody for systemic lupus erythematosus (SLE).

机译：目的该第二阶段试验评估了对系统性红斑狼疮（SLE）的白细胞介素（IL）6单克隆抗体的疗效和安全性。

著录项

来源
《Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research》 |2017年第3期|共9页
作者
Wallace Daniel J.; Strand Vibeke; Merrill Joan T.; Popa Serghei; Spindler Alberto J.; Eimon Alicia; Petri Michelle; Smolen Josef S.; Wajdula Joseph; Christensen Jared; Li Cheryl; Diehl Annette; Vincent Michael S.; Beebe Jean; Healey Paul; Sridharan Sudhakar;
展开▼
作者单位

Cedars Sinai Med Ctr Div Rheumatol Los Angeles CA 90048 USA;

Stanford Univ Div Immunol Rheumatol Palo Alto CA 94304 USA;

Oklahoma Med Res Fdn Dept Pharmacol 825 NE 13th St Oklahoma City OK 73104 USA;

Republican Clin Hosp Kishinev Moldova;

Ctr Med Privado Reumatol San Miguel De Tucuman Argentina;

CEMIC Buenos Aires DF Argentina;

Johns Hopkins Univ Sch Med Baltimore MD USA;

Med Univ Vienna Div Rheumatol Dept Med 3 Vienna Austria;

Pfizer Inc Collegeville MN USA;

Pfizer Inc Cambridge MA USA;

Pfizer Inc Cambridge MA USA;

Pfizer Inc Collegeville MN USA;

Pfizer Inc Cambridge MA USA;

Pfizer Inc Cambridge MA USA;

Pfizer Inc Groton CT 06340 USA;

PPD Inc Rockville MD USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类免疫性疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial [J] . Wallace Daniel J., Strand Vibeke, Merrill Joan T., Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2017,第3期

机译：白细胞介素6单克隆抗体治疗系统性红斑狼疮的疗效和安全性：A II期剂量 - 范围随机对照试验
2. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: A 24-week, randomised, double-blind, placebo-controlled, phase ii proof-of-concept trial [J] . McInnesI.B., SieperJ., BraunJ., Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2014,第2期

机译：secukinumab，一种完全的人类抗白介素17A单克隆抗体，在中度至重度银屑病关节炎患者中的疗效和安全性：为期24周，随机，双盲，安慰剂对照，II期概念验证试用
3. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: A 24-week, randomised, double-blind, placebo-controlled, phase ii proof-of-concept trial [J] . McInnesI.B., SieperJ., BraunJ., Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2014,第2期

机译：Secukinumab的疗效和安全性，一种完全人的抗白细胞介素-17A单克隆抗体，中度至严重的银屑病性关节炎患者：24周，随机，双盲，安慰剂控制，第二期概念证明审判
4. Citrullinated antibodies in systemic lupus erythematosus and primary Sjogren's syndrome [C] . Hullo D., Szdke I., Szollosi I., European Congress of Immunology . 2009

机译：Systullated抗体在Systemic Lupus红斑和原发性Sjogren综合征
5. Immunoregulatory Activities of Novel Anti-inflammatory Cytokine Interleukin-35 on Systemic Lupus Erythematosus: Clinical and in vivo Study. [D] . Cai, Zhe. 2015

机译：新型抗炎细胞因子白细胞介素35对系统性红斑狼疮的免疫调节活性：临床和体内研究。
6. Extended report: Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial [O] . Daniel J Wallace, Vibeke Strand, Joan T Merrill, -1

机译：扩展报告：白介素6单克隆抗体治疗系统性红斑狼疮的疗效和安全性：II期剂量范围随机对照试验
7. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial [O] . McInnes, Iain B., Sieper, Joachim, Braun, Jürgen, 2014

机译：secukinumab，一种完全的人类抗白介素17A单克隆抗体，在中度至重度银屑病关节炎患者中的疗效和安全性：24周，随机，双盲，安慰剂对照，II期概念验证试用

Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial

摘要

著录项

相似文献

相关主题

期刊订阅